IDEXX Laboratories, Inc. - Common Stock (IDXX)

IDEXX raised its 2026 earnings forecast, but it also trimmed its margin outlook. Here’s what is really behind the raise, and why testing demand isn’t the reason.

Diagnostics revenue surged 11% as premium instrument placements expanded globally.

IDEXX Laboratories (NASDAQ:IDXX) reported third-quarter 2026 results marked by organic revenue growth, higher diagnostic utilization and expanded placement of its premium instruments, while raising its full-year revenue and earnings outlook. Chief Financial Officer Andrew Emerson said organic reven

IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure

IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Of

Kingsley exercised options at $114.17 per share before immediately selling at $532.08, capturing a significant gain. His direct stake remains at 9,568 shares worth $5.12 million.

IDEXX Laboratories (NASDAQ:IDXX) outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to incre

Diagnostic innovations fuel 10% CAG recurring revenue growth despite wellness visit pressure.

IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing s

IDEXX Laboratories (NASDAQ:IDXX) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by

As data centers strain water systems, FIW, PHO, and CGW offer investors ETF-based access to water utilities, infrastructure, and equipment firms, each with distinct fees and concentration.

IDEXX Laboratories (NASDAQ:IDXX) President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company’s innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics. Erickson, who recently b